Columbia Laboratories' Names Robert S. Mills New Senior Vice President Operations.

Business Editors/Health & Medical Writers

NEW YORK--(BUSINESS WIRE)--June 14, 2001

Columbia Laboratories (AMEX:COB) today announced that Robert S. Mills has joined the Company as Senior Vice President of Operations responsible for Manufacturing, Manufacturing Logistics, Quality Assurance and Quality Control.

From 1999 to the present, Mr. Mills served as Senior Vice President, Manufacturing Operations at Watson Pharmaceuticals, Inc. where he directed the manufacturing functions resulting from the Watson Schein merger. During this time, he provided leadership and direction to senior management at six pharmaceutical manufacturing facilities worldwide and supervised 1,400 employees. Prior to his employment at Watson, Bob spent twenty-six years in increasingly senior positions at Schein, Alpharma and Aventis.

Commenting on the appointment, Fred Wilkinson, president and chief executive officer of Columbia Laboratories, stated, "I am delighted to have Bob join our management team. He brings an outstanding track record of successful strategic and business implementation skills that have enabled him to maximize the operational capacity of pharmaceutical manufacturing facilities. Bob's background will be important to Columbia as we expand our operational initiatives with a focus toward the US and seek to maximize the products in our development pipeline."

Wilkinson concluded, "His experience in structuring and implementing product development programs can also enhance our operating margins by reducing the costs associated with our manufacturing processes. He brings solid experience in the direction of technical personnel and operations in manufacturing settings."

Columbia Laboratories, Inc. is a US-based international pharmaceutical company dedicated to research and development of women's health care products, including those intended to treat infertility, dysmenorrhea, endometriosis, and hormonal deficiencies. Columbia is also developing hormonal products for men and a buccal delivery system for peptides. Columbia's products primarily utilize the company's patented bioadhesive delivery technology.

This press release contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the intent, belief or current expectations of the company and its management team. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Such risks and uncertainties include, among other things, successful outcomes of clinical studies, competitive economic and regulatory factors in the pharmaceutical and health care industry, general economic conditions and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission.